SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
SciSparc Ltd. (Nasdaq: SPRC) said its subsidiary NeuroThera Labs (TSXV: NTLX) started a Phase IIb clinical trial site at Hannover Medical School in Germany for SCI-110, a cannabinoid-based treatment for adult Tourette syndrome. The randomized, double-blind, placebo-controlled cross-over study follows Phase IIa results showing 21% average tic reduction.
How this was made
The 30-second read
Why it matters
The new fact is the initiation of the German Phase IIb trial site at Hannover Medical School, expanding study execution alongside Yale Child Study Center and Tel Aviv Sourasky Medical Center. This can improve forward visibility into upcoming efficacy and safety readouts at weeks 12 and 26, but it does not change the underlying trial results yet.
Market read
A concrete clinical-development milestone for SCI-110 that can support valuation expectations, with the next tradable catalysts likely tied to enrollment progress and week 12/26 outcomes.
What to watch
Key near-term risks include recruitment timelines, adverse-event profile during longer dosing, and whether the cross-over design shows durable tic reduction at weeks 12 and 26.
Background
SciSparc’s subsidiary NeuroThera is running Phase IIb for SCI-110 (dronabinol plus palmitoylethanolamide) for adult Tourette syndrome after Phase IIa safety/efficacy signals.
Ticker impact
SciSparc announced its subsidiary NeuroThera initiated a Phase IIb trial site in Germany for SCI-110 in adult Tourette syndrome.
Moderate positive bias for SPRC on trial-progress expectations, with volatility tied to future enrollment and interim data.
The article is a fresh clinical-development milestone (Phase IIb site initiation) with defined endpoints, but it does not provide new efficacy/safety results yet.
Market effects
Adds incremental momentum to cannabinoid-based CNS drug development narratives, but without broader sector guidance or regulatory changes.
Highlights Germany and Israel trial execution, potentially supporting cross-border clinical execution credibility.
Tourette syndrome adult treatment development remains an unmet-need area; milestone may influence global peer sentiment toward similar CNS programs.
Counterpoint
Site initiation does not guarantee enrollment speed, dosing adherence, or eventual positive Phase IIb outcomes; the market may already price generic trial progress.
Key entities
- public_companySciSparc Ltd.
Nasdaq-listed parent company announcing NeuroThera’s Phase IIb trial site initiation for SCI-110.
- public_companyNeuroThera Labs Inc.
Clinical-stage subsidiary initiating Phase IIb trial site at Hannover Medical School for SCI-110 in adult Tourette syndrome.
- drug_candidateSCI-110
Proprietary cannabinoid-based treatment candidate (dronabinol plus palmitoylethanolamide) in Phase IIb for Tourette syndrome.
- clinical_siteHannover Medical School (MHH)
German clinical site where the Phase IIb trial is now initiated.
